PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 15, 2026European Journal of Heart Failure0 citations

Restoration Of Protein Quality Control By Empagliflozin In Diabetic HFpEF Patients

Restoration of protein quality control by empagliflozin in diabetic hfpef patients: linking reduced oxidative stress and inflammation to improved cardiac function

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does in vitro treatment with empagliflozin improve protein quality control, inflammation, and cardiomyocyte stiffness in myocardial biopsies from HFpEF patients with diabetes?

Population

Left ventricular myocardial biopsies from patients with HFpEF, with and without type 2 diabetes mellitus

Comparison

In vitro treatment with empagliflozin vs Untreated biopsies and biopsies from HFpEF…

Design

Preclinical

Key result

Empagliflozin improved cardiac function in diabetic HFpEF patients by upregulating the NO-sGC-cGMP-PKG pathway and reducing inflammation and myocardial stiffness.

Authors

SDSimin DelalatISInnas SultanaSZSaltanat Zhazykbayeva

Discussion

Loading...

Member takes

Overview

May explain empagliflozin benefits in diabetic HFpEF; extends mechanistic evidence via the NO-sGC-cGMP-PKG pathway in human myocardium.

Key Points

  • To explore the impact of type 2 diabetes on protein quality control in HFpEF and the effects of empagliflozin on these mechanisms.
  • Analyzed left ventricular myocardial biopsies from HFpEF patients with and without diabetes
  • Investigated the role of protein quality control and its impact on cardiac dysfunction
  • Conducted in vitro treatments with empagliflozin to assess its effects
  • Inflammasome markers were elevated in diabetic HFpEF patients, indicating increased inflammation.
  • EMPA treatment restored the NO-sGC-cGMP-PKG signaling pathway and reduced inflammation.
  • EMPA corrected cardiomyocyte stiffness and improved protein quality control.

Structured PICO

Does in vitro treatment with empagliflozin improve protein quality control, inflammation, and cardiomyocyte stiffness in myocardial biopsies from HFpEF patients with diabetes?

P
Population
Left ventricular myocardial biopsies from patients with HFpEF, with and without type 2 diabetes mellitus (T2DM)
I
Intervention
In vitro treatment with empagliflozin
C
Comparator
Untreated biopsies and biopsies from HFpEF patients without diabetes
O
Outcome
Protein quality control mechanisms, myocardial oxidation, apoptosis, inflammation, and cardiomyocyte stiffnesssurrogate

Empagliflozin improves cardiomyocyte stiffness and reduces inflammation in diabetic HFpEF myocardial biopsies via the NO-sGC-cGMP-PKG pathway, providing mechanistic insights into its clinical benefits.

Cite This Study

Delalat et al. (2026) studied this question. Empagliflozin improved cardiac function in diabetic HFpEF patients by upregulating the NO-sGC-cGMP-PKG pathway and reducing inflammation and myocardial stiffness.

synapsesocial.com/papers/69b64c67b42794e3e660dc0chttps://doi.org/10.1093/ejhf/xuag034.046
View Full Paper
Ask AI
Bookmark
Share